Asgard Therapeutics AB has been admitted to SmiLe Incubator as the next step to move forward on the pre-clinical studies of their lead program TrojanDC. https://news.smileincubator.com/posts/pressreleases/immunotherapy-company-asgard-therapeutics-is
Advanced Therapies Medical Products (ATMPs) are considered the “drugs of the future”. These are based on gene, cell and tissue products. Sweden has the ambitious goal of becoming a leader
Filipe Pereira, Cristiana Pires and Fábio Rosa, co-founders of Asgard Therapeutics, awarded with the Lund University and Sparbanken Skåne’s prize for future innovations
Together with Sparbanken Skåne, in collaboration with the Sparbanksstiftelsen Finn, Lund University awarded Filipe Pereira, Cristiana Pires and Fábio Rosa the Lund University and Sparbanken Skåne’s prize for future innovations.
The BioInnovation Institute (BII) awarded Filipe Pereira, co-founder of Asgard Therapeutics, with DKK 3.5M to advance pre-clinical development of dendritic cell reprogramming and define its regulatory roadmap towards the clinic.
Swedish start-up company Asgard Therapeutics has been awarded the second step of Vinnova’s Innovative Startup program in order to further develop a new cancer immunotherapy based on dendritic cell reprogramming.
Asgard was selected to receive Vinnova’s VFT+ funds managed by LU Innovation for verification activities of TrojanDC towards partners, customers and investors.
Fábio Rosa, co-founder of Asgard Therapeutics, selected for Forbes 30 under 30 List – Europe – Science & Healthcare 2020
Fábio Rosa, co-founder of Asgard Therapeutics, was selected by Forbes among 30 brightest young entrepreneurs, innovators and game changers in Science and Healthcare segment. https://www.forbes.com/profile/fabio-rosa/#7376307670f8
Filipe Pereira, co-founder of Asgard Therapeutics, awarded with European Research Council (ERC) Consolidator Grant
The European Research Council (ERC) awarded Filipe Pereira, co-founder of Asgard Therapeutics, with an ERC Consolidator Grant to harness dendritic cell reprogramming towards the development of new patient-specific strategies for
Asgard Therapeutics won the Nordic Mentor Network for Entrepreneurship (NOME) Nordic entrepreneurship competition for promising life science companies and becomes part of the Novo Nordisk-funded NOME mentoring network.
Swedish start-up company Asgard Therapeutics has been awarded H2020 SMEi phase 1 in order to further develop a direct cell reprogramming technology for cancer immunotherapy. Asgard Therapeutics was founded in
Cristiana Pires, CEO and co-founder of Asgard Therapeutics, receives Audience choice Award at BIOEurope Start-up Slam
Cristiana Pires, CEO and co-founder of Asgard Therapeutics, awarded with ‘Audience Choice’ Award at BIOEurope Start-up Slam pitch competition promoted by J&J Innovation – JLabs. https://www.ebdgroup.com/bio-europe-2019s-startup-slam-winner-eisbach-bio/
Asgard Therapeutics won the Sten K Johnson Grant in the category of Medicine for projects with innovative ideas of medical importance that challenge traditional methods and concepts.